Analyst Ratings For BTG plc (LON:BTG)
Today, Numis Securities Ltd reiterated its Buy rating on BTG plc (LON:BTG) with a price target of GBX 900.
There are 3 hold ratings, 5 buy ratings on the stock.
The current consensus rating on BTG plc (LON:BTG) is Buy (Score: 2.63) with a consensus target price of GBX 765.25 per share, a potential .
Some recent analyst ratings include
- 2/16/2017-Numis Securities Ltd Reiterated Rating of Buy.
- 1/26/2017-Panmure Gordon Reiterated Rating of Buy.
- 1/25/2017-Peel Hunt initiated coverage with a Hold rating.
- 1/17/2017-J P Morgan Chase & Co Reiterated Rating of Neutral.
- 11/3/2016-Stifel Nicolaus Upgrade from a “Buy” rating to a “” rating.
About BTG plc (LON:BTG)
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing. The Interventional Medicine segment includes oncology, vascular and pulmonology. The segment’s products include Beads, TheraSphere, EkoSonic, Varithena and PneumRx Coils for use in the treatment of liver tumors, blood clots, varicose veins and advanced emphysema. The Specialty Pharmaceuticals segment includes CroFab, DigiFab, Voraxaze and Vistogard products for use in the treatment of crotalid envenomation, digoxin toxicity, high-dose methotrexate toxicity and 5-fluorouracil toxicity. The Licensing segment includes Zytiga, Two-Part Hip Cup and Lemtrada products for use in the treatment of advanced prostate cancer, hip replacement and multiple sclerosis.
Recent Trading Activity for BTG plc (LON:BTG)
Shares of BTG plc closed the previous trading session at 555.68 up +1.18 0.21% with 491,227 shares trading hands.